60
Participants
Start Date
April 22, 2024
Primary Completion Date
February 1, 2027
Study Completion Date
February 1, 2029
Pirtobrutinib
"Initial treatment:~\- Pirtobrutinib 200 mg by mouth (PO) daily from Cycle 1 Day 1 until the end of Cycle 12. Each cycle is 28 days.~Re-treatment:~-Pirtobrutinib 200 mg PO daily continuously"
Obinutuzumab
"Obinutuzumab is given intravenously from Cycle 7 to Cycle 12, for total 6 cycles during initial treatment only.~Initial treatment:~\- Obinutuzumab intravenous (IV) following the standard schedule from Cycle 6 through Cycle 12 (total 6 cycles: 100 mg on Cycle 6 Day 1, 900 mg on Cycle 6 Day 2, 1000 mg on Cycle 6 Day 8 and Cycle 6 Day 15, 1000 mg on Day 1 of Cycle 7 through Cycle 12)."
New England Cancer Specialists, Scarborough
Beth Israel Deaconess Medical Center, Boston
Brigham & Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Loxo Oncology, Inc.
INDUSTRY
Inhye Ahn
OTHER